actarit
Small moleculeexperimental
Actarit is a disease-modifying antirheumatic drug (DMARD) developed in Japan for use in rheumatoid arthritis. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Sep 30, 2018 (NCT03660059)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Carbonic anhydraseINHIBITOR
Carbonic anhydrase inhibitor
- Carbonic anhydrase 2 (CA2) ↗
- Carbonic anhydrase 7 (CA7) ↗
- Carbonic anhydrase 1 (CA1) ↗
- Carbonic anhydrase 3 (CA3) ↗
- Carbonic anhydrase 6 (CA6) ↗
- Carbonic anhydrase 12 (CA12) ↗
- Carbonic anhydrase 14 (CA14) ↗
- Carbonic anhydrase 9 (CA9) ↗
- Carbonic anhydrase 4 (CA4) ↗
- Carbonic anhydrase 13 (CA13) ↗
- Carbonic anhydrase 5B, mitochondrial (CA5B) ↗
- Carbonic anhydrase 5A, mitochondrial (CA5A) ↗
- Carbonic anhydrase II
- Carbonic anhydrase III
- Carbonic anhydrase VI
- Carbonic anhydrase I
- Carbonic anhydrase VB
- Carbonic anhydrase VA
- Carbonic anhydrase VII
- Carbonic anhydrase XIV
- Carbonic anhydrase XII
- Carbonic anhydrase IV
- Carbonic anhydrase XIII
- Carbonic anhydrase IX
- Carbonic anhydrases; II & IX
- Carbonic anhydrase V
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaActarit ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03660059 | Phase 3 | Sep 30, 2018 | Astellas |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astellas | For profit | 1 | 1 | 1 | 2018 |
1 organizations
Page 1 / 1